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Although monoclonal antibodies (moab) raised by hybridoma
technology (Köhler and Milstein, 1975) have been demonstrated
to be very useful in research and diagnosis, they are somewhat
problematic as binding moieties in immunotherapeutic agents for
the treatment of tumours. Apart from their relatively large size
(150 kDa), which makes it difficult to penetrate into solid tumours,
these non-human antibodies generate an immune response
resulting in serious side-effects such as serum sickness or anaphy-
lactic shock, which prevent long-term treatment of cancer patients
(Shawler et al, 1985). It is also documented that this human anti-
mouse antibody (HAMA) response causes a rapid blood clearance
of these reagents, which diminishes their efficacy (Khazaeli et al,
1994).
To circumvent these problems, two strategies have been
followed. First, a reduction of the molecular size of the binding
moiety using Fab fragments or even just the variable fragments of
an antibody as a single-chain variable fragment (scFv) has signifi-
cantly reduced the target surface for an immune response and thus
the immunogenicity. Secondly, the use of humanized proteins like
chimaeric or CDR-grafted, or even fully human antibodies or anti-
body fragments, has been demonstrated to reduce their immuno-
genicity (Meredith et al, 1993).
Because of technical problems and difficulties in retrieving suit-
able human donors, it is complicated to raise human hybridomas
by conventional techniques. However, the progress in molecular
biology has offered different ways to evade this restriction. One
possibility is the use of transgenic mice carrying human
immunoglobulin genes. These mice can be used to generate
hybridomas secreting human antibodies (Brüggemann and
Neuberger, 1996). Another way is the use of human V-gene
libraries expressed and displayed on phage and selection of
antigen-specific antibodies therefrom (Hoogenboom, 1997;
Winter et al, 1994). These libraries can be derived from immu-
nized or non-immunized donors or even generated synthetically
(Hoogenboom et al, 1998). Indeed, from very large phage
libraries, high-affinity antibodies to many different target antigens
can be selected (Hoogenboom, 1997). This in vitro selection
procedure is subjected to a series of biases introduced by library
preparation, selection conditions and the screening protocol.
Strong biases in selected populations can arise, in particular when
selecting on complex antigenic targets (Hoogenboom et al, 1999;
Persic et al, 1999).
Therefore, it sometimes remains difficult to retrieve antibodies
with desired properties like recognition of a unique epitope, induc-
tion of a post-binding signal transduction or internalization upon
binding to a cell-surface receptor on the target cell (McCall et al,
1998). Hybridoma-derived antibodies with such characteristics are
sometimes available, and may be converted to human versions
using a method termed ‘guided selection’ (Jespers et al, 1994): by
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two consecutive chain-shuffling procedures, the rodent antibody
domains are swapped for human domains, using phage display
technology (library construction and selection on antigen) to
retrieve the best-matching partner. Our goal was to obtain a fully
human antibody from the well-characterized murine moab Ki-4,
which recognizes the CD30 receptor.
CD30 was originally identified by Schwab et al (1982) as the
antigen abundantly expressed on Hodgkin–Reed Sternberg cells
(H–RS) in primary Hodgkin’s lymphoma and recognized by the
first anti-CD30 moab Ki-1. Expression of CD30 in high copy
numbers on the cell surface has also been reported for a subset of
non-Hodgkin lymphomas (NHL), virally transformed B- and
T-cell lines, a subform of large-cell anaplastic lymphoma (CD30+-
LCAL), embryonal carcinomas, malignant melanomas and
mesenchymal tumours (Gruss and Dower, 1995). The CD30
receptor is therefore a useful clinical and pathological tumour
marker for these diseases and a good target for immunotherapy.
Here we report the synthesis of a human anti-CD30 scFv
(hAK30) on the basis of the murine anti-CD30 moab Ki-4. Murine
moab Ki-4, which shows no detectable cross-reactivity with vital
human organs, has successfully been used as part of a chemically
linked ricin A immunotoxin in vivo (Schnell et al, 1995) and also
as a scFv in a Pseudomonas exotoxin A-based recombinant
immunotoxin in vitro (Klimka et al, 1999). Therefore, we
exchanged the murine variable heavy (VH) and light (VL) chain
genes with human counterparts with respective selections on the
CD30-positive Hodgkin cell line L540. This strategy allowed the
construction of a fully human anti-CD30 scFv (hAK30) with the
same binding specificity as moab Ki-4, and in which only the
VH(CDR3) and framework 4 sequences are derived from the
parental antibody. This scFv may serve as a useful building block
for the synthesis and engineering of different fusion proteins, such
as scFv coupled to toxins, enzymes, or, in connection with other
targeting molecules, as bispecific agents (Huston et al, 1993). It is
a promising candidate to use as immunotherapeutic agent for the
treatment of CD30-positive malignancies.
MATERIAL AND METHODS
Cell lines
The Hodgkin-derived cell line L540 (Diehl et al, 1981) and the
hybridoma cell lines BW702 (Bosslet et al, 1989), Ki-3, Ki-4, Ki-
6, Ki-7 (Horn-Lohrens et al, 1995) and BerH2 (Schwarting et al,
1989) were maintained in RPMI 1640 medium (GIBCO-BRL,
Rockville, MD, USA) supplemented with 10% (v/v) FCS, 100 mg
ml–1 streptomycin, 200 units ml–1 penicillin and 2 mM L-gluta-
mine (10% FCS-medium). All cells were cultured at 37°C in a 5%
CO2 humidified atmosphere.
Bacterial strains and plasmids
E.coli XL1-Blue (supE44, hsdR17, recA1, endA1, gyr, A46, thi,
relA1, lacF¢. proA+ B + lacIq, lacZ_M15, Tn10(tetr)] were obtained
from Stratagene (La Jolla, CA, USA). E.coli TG1 (K12_(lac-pro),
supE, thi, hsdD5/F¢traD36, proA+ B+ , lacIq, lacZ_M15) and E.coli
HB2151 (K12_(lac-pro), ara, nalr, thi/F¢, proA+ B+, lacIq,
lacZ_M15) were purchased from Pharmacia (Uppsala, Sweden).
The phagemid vector pCANTAB6 (McCafferty et al, 1994) is used
for N-terminal fusion of scFv fragments to the minor coat protein
p3 of filamentous phage M13 using Sfi I (Nco I)/Not I restriction
sites. An amber-stop codon between the scFv-gene and the bacte-
riophage gene 3 allows the expression of soluble fragment or
phage-displayed scFv, in an E.coli non-suppressor or suppressor
strain, respectively.
Chain shuffling of murine Ki-4 V-genes
The murine Ki-4 scFv was synthesized as described (Klimka et al,
1999). From this scFv, the CDR3-linker-VL-gene fragment was
amplified by polymerase chain reaction (PCR) using 30 cycles of
94°C for 1 min, 55°C for 1 min and 72°C for 2 min, with the
primers VH-FR3-BACK (5¢-GAC ACG GCY GTR TAT TAC
TGT-3¢) and FD-TET-SEQ (5¢-TTT GTC GTC TTT CCA GAC
GTT AGT-3¢) and the proof-reading Pfu-polymerase (Stratagene,
La Jolla, CA, USA) according to the manufacturer’s instructions.
Simultaneously, human VH genes lacking the CDR3-FR4
sequence were amplified from the pHEN1-human scFv repertoire
made by Marks et al (1991), using the primers pUC-REV (5¢-CAG
GAA ACA GCT ATG AC-3¢) and VH-FR3-FOR (5¢-ACA GTA
ATA YAC RGC CGT GTC-3¢). For PCR assembly of the ampli-
fied fragments, 250 ng of each were combined in a 50 ml mixture
and cycled seven times (94°C for 1.5 min, 65°C for 1 min and
72°C for 2 min) to join the fragments. The reaction mixture was
then amplified for 30 cycles (94°C for 1 min, 55°C for 2 min and
72°C for 2 min) after the addition of the outer PCR primers pUC-
REV/FD-TET-SEQ. Assembly products were digested with Sfi
I/Not I and ligated into the phagemid vector pCANTAB6. The
ligation mix was purified by phenol extraction and ethanol precip-
itation and dissolved in 20 ml H2O. The DNA solution was trans-
fected into 100 ml  E.coli TG1 by electroporation as described
elsewhere (Dower et al, 1988). The cells were grown for 1 h in
2´TY medium at 37°C before plating on 2´TY agar medium
containing 100 mg ampicillin ml–1 and 2% (w/v) glucose
(2´TY-Amp-Glu).
Five different selected human VH genes, determined by DNA-
fingerprint analysis as described elsewhere (Marks et al, 1991)
from 20 CD30-reactive half-human scFvs, were amplified with
primers pUC-REV/VH1-FOR-Xho (5¢-CCG CCT CCA CCA
CTC GAG ACG GTG ACC GTG GTC CC-3¢) using Pfu-poly-
merase, ligated into pCANTAB6 using restriction enzymes Sfi
I/Xho I and electroporated into E.coli XL1-Blue. After sequencing
of the human VH genes, they were cloned into the pHEN1-VL
repertoire (Marks et al, 1991) using the restriction sites Sfi I/Xho I
and transfected into E.coli TG1 by electroporation as described
above. After selection, the human anti-CD30 scFv (hAK30) was
finally cloned into pCANTAB6 using the restriction enzymes
SfiI/NotI for expression as His-tagged protein.
Selection of phage on the Hodgkin-derived cell line
L540
The resulting repertoires of transformed bacteria containing the
murine Ki-4 VL linked to human VH repertoire in phagemid
vector pCANTAB6 or selected human VH-genes linked to the
human VL repertoire in pHEN1, were rescued with helper phage
M13K07 as described (Marks et al, 1991). The selection procedure
is described elsewhere (Klimka et al, 1999). Briefly, 5 ´ 105 L540
cells were incubated with 1 ml of 1 ´ 1013 cfu ml–1 phage in 2%
(w/v) MPBS (2% Marvel skimmed milk powder in PBS) for 1 h at
room temperature (RT). After washing the cells ten times with254 A Klimka et al
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5 ml 2% MPBS and two times with 5 ml PBS by spinning (300 g,
3 min, RT) and resuspending respectively, binding phage were
eluted with 50 mM HCl and remaining cell debris was spun down
(300 g, 5 min, RT) after neutralization with 1 M Tris-Cl, pH 7.4.
Phage-containing supernatant (SN) was mixed with 3 ml
2´TY-Glu medium and used to transfect logarithmically grow-
ing E.coli TG1 cells for 30 min at 37°C before plating on
2´TY-Amp-Glu agar medium.
FACS analysis
Cell binding of phage-displayed scFvs was demonstrated by FACS
analysis. 5 ´ 105 L540 target cells were washed in PBS containing
2% (w/v) skimmed milk powder and 0.05% (w/v) sodium azide
(2% MPBS/N3–) and then incubated for 1 h at 4°C with the respec-
tive phage or moabs Ki-3 or Ki-4 in 2% MPBS/N3– respectively.
Bound phage were detected with a sheep anti-fd serum
(Pharmacia, Uppsala, Sweden; 0.02% (v/v) in 2% MPBS/N3–) and
FITC-labelled rabbit-anti-sheep IgG (Dianova, Hamburg,
Germany; 2% (v/v) in MPBS/N3–). Bound monoclonal antibodies
were detected with FITC-conjugated goat-anti-mouse IgG (Becton
& Dickinson, Heidelberg, Germany); cells were analysed on a
FACScan (Becton & Dickinson). For competition FACS analysis,
approximately 1012 cfu of phage displaying scFv were mixed with
50 ml of unpurified supernatant from hybridomas secreting moab
Ki-3 or moab Ki-4, respectively, resulting in a phage vs moab ratio
of approximately 1/1. The mixtures were incubated with the target
cells and bound phage were subsequently detected as described.
Sequencing
The scFv-genes were sequenced by the dideoxy chain termination
method (Sanger et al, 1977) using Dye-Terminator mix (Perkin
Elmer, Norwalk, CO, USA) and the oligonucleotides FD-TET-
SEQ and pUC-REV. Products of the sequencing reaction were
analysed on a semi-automated ABI Prism sequencer (Perkin
Elmer). The nucleic acid sequences of the V regions were
compared to the Kabat database of V genes (Kabat and Wu, 1991)
and Sanger Centre database (http://www.sanger.ac.uk) to deter-
mine the V-gene family and germline V-gene segments.
Purification of recombinant, human, soluble CD30-His
Cloning of the extracellular part of human CD30 receptor fused to
a His6-tag into the eukaryotic expression vector pcDNA3
(Invitrogen, Groningen, The Netherlands) is described elsewhere
(Barth et al, 2000). 250 ml supernatant of COS-1 cells transfected
with sCD30-His-pcDNA3 plasmid was collected, filtered and
incubated with 2 ml Talon™ resin (Clontech, Heidelberg,
Germany) for 2 h at 4°C for IMAC purification. The resin was
subsequently washed with Tris-buffer (20 mM Trisbase, 100 mM
NaCl, pH 8.0) and Tris-buffer, 5 mM Imidazol until the OD280 nm
dropped to 0.001. The sCD30-His protein was then cluted with
250 mM Imidazol in Tris-buffer and dialysed against PBS ovn
at 4°C.
Purification of scFv
E.coli HB2151, harbouring the respective scFv genes in
pCANTAB6 were used to inoculate 750 ml of 2´TY medium
containing 100 mg ml–1 ampicillin and 0.1% (w/v) glucose. The
culture was grown at 37°C to an OD600 nm of 0.9 and then supple-
mented with 1 mM isopropylthio-b-D-galactoside (IPTG) for
induction of soluble scFv expression. After 4 h of induction at
30°C, the cells were pelleted and resuspended in 8 ml ice-cold
TES (200 mMTris-HCl; 0.5 mM EDTA; 500 mM sucrose). After
incubation for 5 min on ice, 8.8 ml of TES/H2O (1:3) were added
and the bacterial suspension was incubated on ice for an additional
20 min. Bacteria were pelleted, SN was collected and the pellet
was resuspended in 10 ml TES/15 mM MgSO4 and incubated on
ice for 15 min. After centrifugation for 5 min at 300 g the super-
natants were mixed and centrifuged at 13 000 g for 10 min to
remove cell debris. The resulting periplasmic fraction was dial-
ysed against Tris-buffer (20 mM Trisbase, 100 mM NaCl, pH 8.0)
ovn at 4°C and the scFvs were purified by IMAC using Talon™
resin (Clontech, Palo Alto, USA) as described for the sCD30-His
protein.
The human scFv hAK30 was additionally expressed under high-
salt stress induction as described elsewhere (Barth et al, 2000). In
brief, 2 L bacterial culture were grown at 28°C in TB-medium
containing 0.5 mM ZnCl2 and 0.1 M potassium phosphate buffer,
pH 7.5 till OD600nm of 1.6. The culture was supplemented with
0.5 M sorbitol, 0.7 M NaCl, 10 mM betain and after 15 min
expression was induced by addition of 1 mM IPTG. After
overnight growth, bacteria were centrifuged and the pellet was
snap-frozen in liquid nitrogen and resuspended in 75 mM Tris-
buffer, pH 8.0 containing 10% glycerol, 300 mM NaCl, 2 mM
EDTA, 5 mM DTT and Complete™ protease inhibitor
(Boehringer Mannheim, Mannheim, Germany). Proteins were
extracted by sonification and centrifugation, desalted by gelchro-
matography using a desalting column (Pharmacia, Uppsala,
Sweden) and scFv was isolated by IMAC using Ni-NTA resin
(Qiagen, Hilden, Germany).
Eluted protein was thoroughly dialysed against PBS and visual-
ized by gelfiltration, SDS-PAGE and immunoblotting. The final
concentration was determined from a scanned Coomassie-stained
SDS-PAGE with BSA-dilutions as standards and performing
densitometrical analysis with Multi-Analyst software (Bio-Rad,
Munich, Germany).
Determination of relative binding affinities of anti-CD30
antibodies
To determine the relative binding affinities of the anti-CD30 anti-
bodies, purified recombinant sCD30-His (70 nM) was incubated
for 1 h at RT in duplicates, with dilution series of the respective
purified scFvs, the Ki-4 Fab fragment prepared as described else-
where (Smith, 1993), or the moab Ki-4, respectively. Unbound
sCD30-His antigen was detected in a CD30 (Ki-1 antigen)-ELISA
kit (DAKO, Glostrup, Denmark) where the coated anti-CD30 anti-
body BerH2 binds to the same CD30-epitope as the investigated
antibodies. sCD30-His captured by BerH2 was detected by perox-
idase-conjugated anti-CD30 antibody Ki-1, which binds to a
different epitope. The ELISA was performed according to the
manufacturer’s instructions and extinction at 450 nm was
measured. The antibody concentration at which the OD450 dropped
to 50% of maximum extinction was taken as the apparent Kd.
Measurement of shed sCD30 receptor
2 ´ 105 L540 cells were washed three times with 10 ml fresh 10%
FCS medium and incubated with 1/10 diluted supernatants ofHuman anti-CD30 scFv by guided selection 255
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different anti-CD30 hybridomas or approx. 0.5 mg ml–1 purified
Ki-4 Fab-fragment, mKi-4 scFv, A12 scFv or hAK30 scFv in 1 ml
10% FCS medium, respectively, to ensure an excess of antibody
against the CD30 receptor on the cell surfaces. After 2 h, the cells
were washed three times in 10 ml 10% FCS medium by centrifu-
gation (300 g) and resuspension to remove unbound antibodies,
before the cells were incubated for further 24 h. 100 ml of cell-free
supernatants were checked for the level of shed extracellular
CD30 receptor using the CD30 (Ki-1 antigen)-ELISA kit (DAKO,
Glostrup, Denmark). Relative OD450 extinction was determined
and compared to the sCD30-level of cells incubated with
hybridoma supernatant of an anti-GD2 antibody (BW702) as
control.
RESULTS
Cloning of V genes and selection of the half-human and
human anti-CD30 scFv
To retrieve a fully human anti-CD30 scFv, the strategy of ‘guided
selection’ (Figure 1) was followed using a recently-cloned murine
anti-CD30 scFv (mKi-4 scFv) as guiding molecule. First, the
CDR3-linker-VL gene fragment of the murine anti-CD30 Ki-4
scFv was combined with a repertoire of CDR3-truncated human
VH genes taken from a repertoire of 1.8 ´ 108 human scFv clones
(Marks et al, 1991). Phage displaying these combinatorial scFvs
were selected for binding to the CD30-positive cell line L540. As
documented in Table 1A, two rounds of selection and amplifica-
tion were sufficient to enrich for CD30-binding, half-human scFv
bearing phage (human VH-murine VL) up to 80%, as determined
in a whole-cell ELISA using L540 cells. DNA-fingerprint analysis
of 12 individual clones with the restriction enzyme BstN I
revealed five different patterns in DNA-gel electrophoresis
(Figure 2A). The scFv-genes of five representative clones were
sequenced and the deduced amino-acid sequences were compared
with the Kabat database and the Sanger Centre database of human
VH-genes to determine their V-gene family and their closest
germline match.
As depicted in Table 2, all five V-genes belong to the VH-I
family, with two VH-genes showing the highest homology to the
VH DP-75 segment. This segment is also the gene with the highest
homology towards the murine VH sequence. The deduced amino-
acid sequences of the human and murine Ki-4 heavy-chain CDR1
and CDR2 show a homology of 23–50% (Table 3). However,
structural analyses, as far as they can be predicted from the amino-
acid sequence (Chothia et al, 1989; 1992), revealed that similar
classes of canonical structures for the human and the murine
VH-genes occurred.
Table 1 Selection of half-human (A) and human (B) anti-CD30 phage antibodies on Hodgkin cell line L540.
Frequency of
Input titre Output titre Ratio positive clones in
Phage clones (cfu) (cfu) (output/input) whole-cell ELISAa
A
Before selection – – – 0 of 94 (0%)
1st round of selection 4 ´ 1013 2 ´ 107 5 ´ 10–7 47 of 94 (50%)
2nd round of selection 2 ´ 1012 4 ´ 109 2 ´ 10–3 75 of 94 (80%)
B
Before selection – – – n.d.
1st round of selection 2 ´ 1013 2 ´ 106 1 ´ 10–7 n.d.
2nd round of selection 4 ´ 1013 1 ´ 107 2.5 ´ 10–7 0 of 94 (0%)
3rd round of selection 6 ´ 1013 5 ´ 108 8.3 ´ 10–6 7 of 93 (8%)
aClones have been stated as positive if OD490 nm was three times higher than background; cfu, colony forming unit; n.d., not determined.
Murine Ki-4 scFv
human anti-CD30 scFv
mVH mVL
hVH hVL hVH mVL gene 3
hVHs mVL gene 3
mVH mVL gene 3
Linker
Linker
Linker
VL-gene-shuffling
VH-segment-shuffling
hVH hVLs gene 3
Antigen on cell surface
Antigen on cell surface
Rescue of phage and selection
for binders using the cell line L540
Amplification of hVH including
the murine VH-CDR3 and
cloning into hVL repertoire
using Sfi I/Xho I restriction sites
Amplification of murine
VL-gene including the VH-
CDR3 and assembly with a
human VH-gene repertoire
Rescue of phage and selection for binders
using the CD30 expressing cell line L540
Figure 1 Schematic drawing of the chain-shuffling procedure used for the guided selection of the human anti-CD30 scFv hAK30. The gene 3 encodes the
phage minor coat protein p3 and is part of the phagmid vector pCANTAB6.256 A Klimka et al
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The five selected human VH-genes were PCR-amplified and
cloned into the phagemid vector pCANTAB6. After sequencing
the VH-genes once more, they were pooled and cloned into a 4.5 ´
106 member human (h)VL phage antibody library in pHEN-1
(Marks et al, 1991) resulting in a combinatorial library of 8 ´ 106
individual clones. Three rounds of phage selection and amplifica-
tion were performed using the Hodgkin-derived cell line L540,
which resulted in 8% binders in a whole-cell ELISA (Table 1B).
DNA-fingerprint analysis showed that all positive clones contain
the same human VH- (from half-human clone A12) and human
VL- gene (Figure 2B), which was subsequently confirmed by
sequencing two of these clones. The deduced amino-acid sequence
of the selected human VL-gene (Table 2) shows that it possesses a
41%-homology to the parental murine VL-gene in the CDR
regions and retains similar structural elements (Table 3). The
DNA-sequence of the final human anti-CD30 scFv hAK30 was
submitted to GenBank (accession number AF117956).
Binding properties of the half-human and human anti-
CD30 scFvs
To verify binding specificity of the scFvs against the CD30-
epitope recognized by the monoclonal Ki-4 antibody, competition
experiments were performed and evaluated by FACS analysis. As
shown in Figure 3, binding of the selected scFvs displayed on
phage was partially but specifically blocked by the parental Ki-4
moab, but not by the monoclonal Ki-3 antibody, which recognizes
a different epitope on the CD30 antigen (shown for mKi-4 scFv,
h/mA12 scFv, and human hAK30 scFv). The scF-v-genes were
subsequently expressed in E. coli non-suppressor strain HB2151
Table 3 V-gene classifications, structural predictions of the CDR-loops and homologies of V-genes involved in the chain-shuffling procedure
Predicted canonical structure of Human germline Amino-acid sequence
CDR loopsb gene with closest homology (%) of CDRs
V-genes V-gene familya H/L 1 H/L 2 H/L 3 deduced protein towards murine Ki-4
sequencec
mVH-Ki-4 Mo-VH VII 1 2 n.a. VH DP-75 100
hVH A9 Hu-VH1 1 2/3 n.a. VH hv1f10t 36
hVH A3 Hu-VH1 1 2 n.a. VH VHGL-1.8 32
hVH A4 Hu-VH1 1 2 n.a. VH DP-10 23
hVH E2 Hu-VH1 1 2/3 n.a. VH DP-75 50
hVH A12 Hu-VH1 1 2/3 n.a. VH DP-75 50
(hAK30)
mVL-Ki-4 Mo-VkXXI 2 1 1 Vk DPK-24 100
hVL-4 (hAK30) Hu-Vk12 11 V kL12a+ 41
aV-gene families assigned to Kabat database (http://immuno.bme.nwu.edu/famgroup.html); bCanonical structures were determined according to Chothia et al
(1989; 1992); cgermline genes assigned to Sanger Centre database (http://www.sanger.ac.uk); n.a., not applicable
A
B
Figure 2 Bst NI fingerprint-analysis of positive scFv clones determined by whole-cell ELISA using cell line L540. The scFv inserts were PCR-amplified from
individual colonies using vector-based primers according to Marks et al (1991). The products were digested with Bst NI and analysed on agarose gels.
M, 100 bp molecular weight marker. (A) Digests from colonies with half-human scFvs after 1 round of selection (lanes 1 to 10) and 2 rounds of selection
(lanes 11 to 22). (B) Lanes 1 to 7 are digest, from colonies with human scFvs after 3 rounds of selection.
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and purified by IMAC. The typical yield of purified scFv was
approximately 150 mg l–1 bacterial culture performing a standard
periplasmic extraction, or twice as much using a modified protocol
(see Material and methods).
The relative binding affinities were determined by ELISA using
a defined concentration of purified sCD30-His protein as antigen
and dilution series of the indicated anti-CD30 antibodies (Figure
4). Purified scFv antibodies consisted of at least 95% monomeric
molecules demonstrated by gelfiltration (data not shown). Antigen
and antibodies were incubated in solution and unbound antigen
was subsequently quantified with a coated anti-CD30 antibody,
recognizing the same epitope as the investigated antibodies. The
antibody concentration at which 50% of the antigen was bound at
equilibrium was taken as the apparent Kd. The relative affinities of
the moab Ki-4 Fab-fragment, the murine Ki-4 scFv and the half-
human anti-CD30 scFv A12 are approximately 10-fold higher than
the affinity of the human scFv hAK30 (Table 4), but 10-fold lower
than the whole, bivalent monoclonal antibody Ki-4.
Shedding-inhibition of the extracellular part of the
CD30 receptor
To investigate the influence of our recombinant anti-CD30 anti-
bodies on the shedding of the extracellular part of the CD30
receptor, L540 cells were incubated with supernatants of different
anti-CD30 hybridomas or purified recombinant anti-CD30 scFvs,
respectively. After 2 h, the cells were thoroughly washed with
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Figure 3 Histograms of FACS-analysis for determination of the CD30-
epitope specificity of the selected anti-CD30 scFvs. (A) L540-cells were
incubated with anti-CD30 Ki-3- (filled area), Ki-4 (unfilled area) hybridoma-
supernatant or PBS (dotted line) and binding was detected by FITC-
conjugated goat-anti-mouse IgG antibody. (B) L540 cells were incubated with
phage displaying no scFv (dotted line) or phage displaying half-human scFv
A12 (black line). L540 cells were incubated with phage-antibodies mKi-4 (C),
h/mA12 (D) or hAK30 (E) and additionally with anti-CD30 moab Ki-3- (black
line) or Ki-4- (dotted line) hybridoma-supernatant, respectively. Binding of
phage-antibodies was subsequently detected using sheep-anti-M13-serum
and FITC-conjugated rabbit-anti-sheep-IgG antibody.
10–13 10–12 10–11 10–10 10–9 10–8 10–7 10–6 10–5
Antibody concentration (M)
0,000
0,025
0,050
0,075
0,100
0,125
0,150
0,175
R
e
l
a
t
i
v
e
 
O
D
 
4
5
0
 
n
m
Figure 4 Apparent binding affinities of anti-CD30 antibodies using
recombinant sCD30-His antigen. Dilution series of anti-CD30 antibodies
moab Ki-4 — s —, Ki-4 Fab-fragment — l—, mKi-4 scFv — s s—,
h/mA12 scFv — l l— and hAK30 scFv — n n—were incubated with recombinant
sCD30-His protein and unbound antigen was detected by CD30-ELISA
(DAKO).
Table 4 Apparent affinities of anti-CD30 antibodies
Anti-CD30 antibody Kd (M)
moab Ki-4 4 ´ 10–10
Ki-4 Fab-fragment 5 ´ 10–9
mKi-4 scFv 3 ´ 10–9
h/mA12 scFv 7 ´ 10–9
hAK30 scFv 3 ´ 10–8
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–1,1
–0,9
–0,7
–0,5
–0,3
–0,1
0,1
0,3
moab BW702
moab BerH2
moab Ki-6
moab Ki-7
Ki-4 scFv
hAK30 scFv
h/m A12 scFv
Ki-4 Fab-fragment
moab Ki-4
moab Ki-3
Figure 5 Influence of anti-CD30 antibodies towards naturally occuring
CD30 receptor cleavage from Hodgkin-derived L540 cell line. Cells were
incubated for 2 h with indicated antibodies and shed CD30 receptor was
detected by CD30-ELISA (DAKO). Value of relative OD450 of the control,
using an irrelevant anti-GD2 antibody (BW702), was set as zero baseline.Human anti-CD30 scFv by guided selection 259
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medium to deplete unbound antibodies. After another 24 h of incu-
bation, supernatants were checked for sCD30-level in a CD30 (Ki-
1 Antigen) ELISA kit (DAKO) in duplicates. Figure 5 shows that,
as was described by Horn-Lohrens et al (1995), Ki-4 and BerH2
strongly inhibit the shedding of the extracellular part of CD30
receptor (sCD30), whereas Ki-3, Ki-6 and Ki-7 increased the
sCD30 level to different extents. The recombinant Ki-4-derived
anti-CD30 antibodies and the monovalent moab Ki-4 Fab frag-
ment exhibit a comparable inhibition of the cleavage of CD30
receptor from L540 cells, although they are not as potent as the
bivalent moabs Ki-4 and BerH2.
DISCUSSION
In this paper, we report the cloning of a human anti-CD30 scFv by
guided selection from the murine anti-CD30 scFv Ki-4 using the
phage display technology. In contrast to other described
procedures (Jespers et al, 1994; Figini et al, 1994), we retained the
VH-CDR3 region of the parental murine scFv in this guided selec-
tion. This particular region is not only known for its significant
importance in determining the binding specificity of an antibody, it
is also a highly variable region in every antibody, which makes it
less likely to be a major immunogenic part of the molecule. We
believe that this region was important in retaining the CD30-
epitope specificity of the parental antibody in the human scFv.
Watzka et al (1998) describe the humanization through chain-shuf-
fling of an anti-human interferon g receptor 1 antibody without
retaining the VH-CDR3 region of the murine antibody. The
resulting fully-human Fab-antibody was antigen specific, but
differed in epitope specificity from the parental hybridoma,
thereby underlining the importance of the VH-CDR3. This impor-
tance of the VH-CDR3 for epitope specificity has also recently
been reported by Beiboer et al (2000), thereby confirming our
findings.
Selection of phage libraries in this study was performed on a
Hodgkin-derived cell line which is known for its high surface
expression of CD30 receptor (106 receptor molecules per cell),
rather than by panning on recombinant CD30 antigen. CD30 is
part of the TNF receptor family and many ligands and receptors
are known to trimerize. It may therefore not be straightforward to
retain natural epitopes on recombinant versions of such cell-
surface molecules. Therefore, cell panning on CD30-positive cells
is a good and valid alternative. Indeed, using recombinant CD30
protein for panning of several human scFv phage repertoires, to
date other groups were unsuccessful in retrieving functional 
anti-CD30 antibodies.
The selection on cells and therefore native CD30 receptor
resulted in five different human VH genes with homology in the
CDR1 and CDR2 regions between 23–50%, compared with the
parental murine Ki-4 heavy chain. This is similar to what was
found in the group of Watzka et al (1998) for their selected anti-
human interferon g receptor antibody (45%), and higher than
described in the study of Figini et al (1998), in which an anti-
ovarian carcinoma Fab fragment was humanized by guided selec-
tion. However, more important than sequence homology might be
the length of the CDR regions and the canonical structure of the
CDR-loops defined by Chothia et al (1989; 1992). This was
striking in the case described by Figini et al (1994) retrieving a
human anti-phOx Fab fragment by guided selection which shared
these structural elements with the parental mouse antibody. In our
study, the selected human VH gene with the highest sequence
homology towards mKi-4 VH, but probably slightly different
canonical folds, is the one of the half-human anti-CD30 scFv A12.
This clone was also predominant after the selection (Figure 2A).
Additionally, this human VH gene was selected out of five others
after shuffling with the human VL-repertoire. The human VL gene
of the finally selected human anti-CD30 scFv has the same length
and predicted canonical structure of the CDR-regions as the mKi-
4 VL gene, and a 41% homology of the deduced amino-acid
sequences concerning these regions. This follows the prediction
made by Jespers et al (1994) that there may be a strong preference
for retaining V-gene segments with identical canonical folds in
guided selection procedures.
Expression of the human anti-CD30 scFv hAK30 as soluble
fragment revealed a 10-fold lower apparent Kd for the hAK30 scFv
compared with the mKi-4 scFv (Table 4). A loss in affinity after a
guided selection procedure has also been reported by other groups
(Figini et al, 1998). However, the hAK30 scFv reveals an affinity
in the nanomolar range and is therefore expected to be adequate
for use as targeting moiety in recombinant immunotherapeutics, in
particular when re-formatted as bivalent molecule (Tai et al,
1995). The relative affinity of the monovalent Ki-4 Fab-fragment
(5 ´ 10–9 M) is comparable to the value measured for the mKi-4
scFv and underlines the successful cloning of the functional
V-genes from the hybridoma Ki-4. The higher affinity of the biva-
lent moab Ki-4 (3.7 ´ 10–10 M) most probably is caused by an
avidity effect in the assay.
The monoclonal antibody Ki-4, as well as the moab BerH2,
significantly inhibit the naturally occurring shedding of the extra-
cellular part of the CD30 receptor, as demonstrated by Horn-
Lohrens et al (1995). Since this is a desired property for an
anti-CD30 antibody as part of an immunotherapeutic agent, we
were especially interested in retaining the epitope-specificity of
the moab Ki-4 in our human anti-CD30 antibody. As shown in
Figure 3, the epitope-specificity was retained for the murine and
the human scFv. Although the binding of phage antibodies was not
completely inhibited by moab Ki-4, which might be due to higher
avidity effects of phage (displaying up to five scFv molecules on
their surface), competition for binding was not observed by addi-
tion of moab Ki-3. The anti-sCD30-shedding property was
retained as well, although it was significantly weaker for the
monovalent anti-CD30 molecules, which correlates with their
apparent binding affinities (Figure 5). A bivalent scFv, like a
diabody, may even be as potent as the bivalent moab Ki-4
regarding the CD30-shedding inhibition. Whether the human anti-
CD30 scFv hAK30 will be as potent as the murine Ki-4 scFv as
part of an anti-CD30 immunotherapeutic agent (Klimka et al,
1999) has to be further analysed, e.g. by fusing it to a human-
derived toxin gene (Newton et al, 1996) in order to get a fully
human, recombinant immunotoxin.
In summary, we have been able to derive a functional human
anti-CD30 scFv (hAK30) from the murine anti-CD30 scFv Ki-4
by guided selection using human V-gene repertoires and phage
display technology. The hAK30 scFv retains the epitope speci-
ficity of its murine counterpart and inhibits the shedding of the
CD30 receptor from the cell surface.
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